GlaxoSmithKline's breast cancer drug Tyverb has been turned down again in a final assessment by the cost-effectiveness watchdog.
The National Institute for Health Clinical Excellence, which assesses drugs for reimbursement on the state health service, said on Thursday the treatment had limited benefits and was too expensive, even after a special deal offered by Glaxo.
The final appraisal follows preliminary rebuffs last year and is a blow for Europe's biggest drugmaker, which has been looking to Tyverb -- also known as Tykerb or lapatinib -- to spearhead its expanding business in cancer.
More from Reuters' Ben Hirschler
No comments:
Post a Comment